From Root Cause to Real Impact
A portfolio of RNA therapeutics for areas of urgent medical need.
The Engine Behind Every Program
01A Platform that Translates Regulatory Genome Insights into RNA-Guided Therapeutics
Each program starts with a deep understanding of the mechanistic drivers of disease grounded in the regulatory genome. This enables the creation of scientifically differentiated, first-in-class RNA therapeutic candidates aimed at addressing areas of high unmet medical need.
Programs
02Pipeline
* The FDA has granted Fast Track designation for HTX-001 for the treatment of symptomatic nHCM. Fast Track designation does not mean the drug is effective or safe, or that it will be approved. HTX-001 is an investigational new drug. It has not been approved by any regulatory authority, and its safety and efficacy have not been established.
Creating a New Paradigm in Drug Development
An accelerated path from target discovery to clinical validation powered by HAYA’s Engine.
Our Strategic Focus
03While HAYA’s Engine is versatile, our internal pipeline prioritizes fibrotic, metabolic, and age-related diseases, areas where causal, cell-state-directed medicines can shift the standard of care.
Our Promise
04SANE Medicines for Complex Disease
Safe, Accessible, Needed, Effective
Partnerships & Investors
05Partnering to Translate Causal Biology into Real-World Therapies
Get involved to learn more about our innovative platform and programs.